KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Depreciation & Amortization (IS)EBIATLeasesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - OtherShares OutstandingShares Outstanding
Ratios

TherapeuticsMD (TXMD) Amortization - Deferred Charges (2020 - 2022)

TherapeuticsMD filings provide 3 years of Amortization - Deferred Charges readings, the most recent being $2.6 million for Q3 2022.

  • On a quarterly basis, Amortization - Deferred Charges rose 74.81% to $2.6 million in Q3 2022 year-over-year; TTM through Sep 2022 was $21.1 million, a 317.92% increase, with the full-year FY2021 number at $5.7 million, up 124.68% from a year prior.
  • Amortization - Deferred Charges hit $2.6 million in Q3 2022 for TherapeuticsMD, down from $7.9 million in the prior quarter.
  • In the past five years, Amortization - Deferred Charges ranged from a high of $9.0 million in Q1 2022 to a low of $372000.0 in Q2 2020.
  • Median Amortization - Deferred Charges over the past 3 years was $1.4 million (2021), compared with a mean of $2.7 million.
  • Biggest five-year swings in Amortization - Deferred Charges: soared 54.98% in 2021 and later surged 611.32% in 2022.
  • TherapeuticsMD's Amortization - Deferred Charges stood at $887000.0 in 2020, then soared by 72.6% to $1.5 million in 2021, then skyrocketed by 68.65% to $2.6 million in 2022.
  • The last three reported values for Amortization - Deferred Charges were $2.6 million (Q3 2022), $7.9 million (Q2 2022), and $9.0 million (Q1 2022) per Business Quant data.